Short answer
Viridian Therapeutics, Inc.\DE (VRDN) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 text contains only exhibit liability and incorporation disclaimers.
Viridian Therapeutics, Inc.\DE 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 text contains only exhibit liability and incorporation disclaimers
- No fiscal-year 2026 operating results or financial figures disclosed in the provided excerpt
Item EX-99.1 · Exhibit EX-99.1
- Lumvoa FDA-approved June 26 and launched immediately, transitioning Viridian into commercial operations with early physician and payer traction
- Sales team engaged 95% of 2,000 core prescribing physicians; first doses administered in July, supporting initial demand but not yet revenue scale
- Cash, equivalents, and marketable securities reached $981.5M, supported by $394M gross convertible debt and equity financing
- Q2 net loss widened to $127.1M from $100.7M as SG&A rose to $55.0M for Lumvoa commercial infrastructure
- Elegrobart BLA submission remains targeted for Q1 2027, potentially adding a self-administered subcutaneous TED option to Viridian’s portfolio
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Viridian Therapeutics, Inc.\DE 8-K filings
Get the next VRDN 8-K as it lands
Follow VRDN for push alerts, or ask the research agent what this filing means.